PMID: 33580918

Severe adverse events during sirolimus "off-label" therapy for vascular anomalies.

Rössler J, Baselga E, Davila V, Celis V, Diociaiuti A, El Hachem M, Mestre S, Haeberli D, Prokop A, Hanke C, Loichinger W, Quéré I, Baumgartner I, Niemeyer CM, Kapp FG.Pediatr Blood Cancer. 2021 Feb 13:e28936. doi: 10.1002/pbc.28936. Online ahead of print.PMID: 33580918

PMID: 33231291

Additive value of transarterial embolization to systemic sirolimus treatment in kaposiform hemangioendothelioma.

Brill R, Uller W, Huf V, Müller-Wille R, Schmid I, Pohl A, Häberle B, Perkowski S, Funke K, Till AM, Lauten M, Neumann J, Güttel C, Heid E, Ziermann F, Schmid A, Hüsemann D, Meyer L, Sporns PB, Schinner R, Schmidt VF, Ricke J, Rössler J, Kapp FG, Wohlgemuth WA, Wildgruber M.Int J Cancer. 2021 May 1;148(9):2345-2351. doi: 10.1002/ijc.33406. Epub 2020 Dec 3.PMID: 33231291

PMID: 29405800

Sirolimus-induced regression of a large orbital lymphangioma.

Lagrèze WA, Joachimsen L, Gross N, Taschner C, Rössler J.Orbit. 2019 Feb;38(1):79-80. doi: 10.1080/01676830.2018.1436569. Epub 2018 Feb 6.PMID: 29405800

PMID: 27706796

Sirolimus is highly effective for lymph leakage in microcystic lymphatic malformations with skin involvement.

Rössler J, Geiger J, Földi E, Adams DM, Niemeyer CM.Int J Dermatol. 2017 Apr;56(4):e72-e75. doi: 10.1111/ijd.13419. Epub 2016 Oct 5.PMID: 27706796 No abstract available.

PMID: 27167017

Life-Threatening Cutaneous Bleeding in Childhood Klippel-Trenaunay Syndrome Treated With Oral Sirolimus.

Bessis D, Vernhet H, Bigorre M, Quéré I, Rössler J.JAMA Dermatol. 2016 Sep 1;152(9):1058-9. doi: 10.1001/jamadermatol.2016.1008.PMID: 27167017 No abstract available.